Skip to content

Join The Lazy Contractor's Blueprint live on Nov 28 — show up and get $50 in free Mindy creditsJoin The Lazy Contractor's Blueprint, free and live on Nov 28

Register free
Home/Contractors/Amgen INC./contracts

Federal Contractor Profile

Amgen INC.

$1.1B obligated·19 awards·3 agencies·3 NAICS
OverviewContractsAgenciesNAICS

Federal Contracts

Showing award actions 1–5 of 5 funded award actions, most recent first.

Contracts with positive obligations
19
Funded award actions shown
5
Obligations shown
$1.1B
Awarding agencies
3

This table shows award actions with a positive obligation. Zero-dollar and negative-dollar actions, such as administrative changes and deobligations, are not displayed. Multiple award actions may belong to the same contract.

Award data as of June 2, 2026. Source: USAspending federal award records.

DateAgencyPIIDNAICSDescriptionAmount
Sep 4, 2025Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA75A50119C00061541714THIS CONTRACT IS TO ADVANCE THE DEVELOPMENT OF ROMIPLOSTIM FOR TREATMENT OF HEMATOPOIETIC SUBSYNDROME-ACUTE RADIATION SYNDROME (HS-ARS) AND CHEMOTHERAPY-INDUCED THROMBOCYTOPENIA (CIT) AND A DRUG DELIVERY DEVICE FEASIBILITY PROJECT WITH AN OPTION TO$2.3M
Aug 22, 2023Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA75A50123C00040325412NPLATE ADMINISTRATION KIT DEVELOPMENT FOR THE TREATMENT OF APPROVED INDICATIONS, INCLUDING ACUTE RADIATION SYNDROME (ARS)$7.3M
Jul 20, 2022Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA75A50119C00061541714THIS CONTRACT IS TO ADVANCE THE DEVELOPMENT OF ROMIPLOSTIM FOR TREATMENT OF HEMATOPOIETIC SUBSYNDROME-ACUTE RADIATION SYNDROME (HS-ARS) AND CHEMOTHERAPY-INDUCED THROMBOCYTOPENIA (CIT) AND A DRUG DELIVERY DEVICE FEASIBILITY PROJECT WITH AN OPTION TO$475K
Jan 31, 2022Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA75A50119C00061541714THIS CONTRACT IS TO ADVANCE THE DEVELOPMENT OF ROMIPLOSTIM FOR TREATMENT OF HEMATOPOIETIC SUBSYNDROME-ACUTE RADIATION SYNDROME (HS-ARS) AND CHEMOTHERAPY-INDUCED THROMBOCYTOPENIA (CIT) AND A DRUG DELIVERY DEVICE FEASIBILITY PROJECT WITH AN OPTION TO$2.2M
Sep 26, 2019Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA75A50119C00061541714THIS CONTRACT IS TO ADVANCE THE DEVELOPMENT OF ROMIPLOSTIM FOR TREATMENT OF HEMATOPOIETIC SUBSYNDROME-ACUTE RADIATION SYNDROME (HS-ARS) AND CHEMOTHERAPY-INDUCED THROMBOCYTOPENIA (CIT) AND A DRUG DELIVERY DEVICE FEASIBILITY PROJECT WITH AN OPTION TO$21M

Get Alerted Before Amgen INC.'s Next Recompete

Mindy monitors active contracts and flags recompetes 12 months out so you can position to compete.

Start for free